New drug candidates of the GLP-1 class target metabolic dysfunction-associated steatohepatitis (MASH) in addition to diabetes and obesity.

Global pharmaceutical companies, such as Novo Nordisk, Eli Lily, Boehringer Ingelheim, and Korean pharmaceutical companies, including Dong-A ST and D&D pharmatech, are developing GLP-1 agents for the treatment of MASH.

GLP-1 can aid weight loss by increasing fullness and can enhance blood glucose control by increasing insulin secretion and sensitivity. Weight loss can have a positive impact on patients, as MASH occurs when fat saturates in the liver of individuals who have had low or no alcohol consumption. Nonetheless, pharmaceutical companies are workin